

**Important Notes:**

1. Manulife Global Fund – China Value Fund (“Manulife China Value Fund” or the “Fund”) invests in equity securities of companies with substantial business interests in the Greater China region, which may involve risks relating to equity market, geographical concentration, political and regulatory, Mainland China investment, Mainland China tax, small cap, liquidity and Volatility, currency risks, and is subject to greater risk than investments in more developed economies or markets.
2. The Fund intends to use financial derivative instruments (“FDIs”) for investment, efficient portfolio management and/or hedging purposes. The use of FDIs exposes the Fund to additional risks, including leverage risk, management risk, market risk, credit risk and liquidity risk.
3. Investment involves risk. The Fund may expose its investors to capital loss. Investors should not base on this material alone to make investment decisions and should read the offering document for details, including the risk factors, charges and features of the Fund and its share classes.



**Manulife**  
Investments

2025 Q3

# Manulife China Value Fund

[manulifeim.com.hk](https://manulifeim.com.hk)

# Greater China equities

Powering up on technology, localization and globalization

## 5 reasons for investing in Greater China equities



### China's self-dynamics

- China is ready to step up policy actions to stimulate demand & growth.



### Localization

- China is progressing well on import substitution/localization.



### Technology advancement

- China accelerates on its technology roadmap.
- Taiwan Region is a leader in advanced node foundries.



### Next generation of AI supply chain

- Taiwan Region has a comprehensive tech supply chain ranging from foundries, CPU/GPU substrates, servers, ODM to network switches, which benefit from AI adoption boom.




### Return to capital

- China corporates are 'valuing up'.


## Key features

1) Active approach across all sectors, market cap range and share type of Greater China (China/Hong Kong/Taiwan) equity

### Breakdown by sector weights (%)



### Breakdown by caps (%)



### Universe


<b>Chinese stocks listed in Hong Kong</b> H-shares, red chips, private enterprises	<b>Taiwan equities</b> Taiwan listed stocks	<b>Hong Kong equities</b> Hong Kong listed stocks
<b>Chinese stocks listed in the US</b> ADR	<b>A-shares</b> via stock connect	<b>B-shares</b>

- We believe that there are **four megatrends** (expressed via the 4As positioning) that present growth opportunities, which the team invests via the Growth, Cash Flow, Management and Valuation (GCMV) lens.

Advanced manufacturers and beneficiaries of humanoid robotics supply chain

The information in this material may contain projections or other forward-looking statements regarding future events, targets, management discipline or other expectations, and is only as current as of the date indicated. There is no assurance that such events will occur, and may be significantly different than that shown here. The information in this material including statements concerning financial market trends, are based on current market conditions, which will fluctuate and may be superseded by subsequent market events or for other reasons.

- 



**BENCHMARK**  
FUND OF THE YEAR  
AWARDS 2024

**USD 492 million**  
assets under management<sup>4</sup>

Unless otherwise stated, all information sources are from Manulife Investment Management, as of June 30, 2025. Projections or other forward-looking statements regarding future events, targets, management discipline or other explanations are only current as of the data indicated. There is no assurance that such events will occur, and if they were to occur, the result may be significantly different than that shown here. Investment involves risk. Investors should not make investment decisions based on this material alone and should read the offering document for details, including the risk factors, charges and features of the product. This material has not been reviewed by the Securities and Futures Commission. Issued by Manulife Investment Management (Hong Kong) Limited.

